BIM
CARM

BlackRock Investment Management’s Carisma Therapeutics CARM Stock Holding History

BlackRock Investment Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-90
Closed -$1K – 4046
2016
Q1 		$1K Hold
90
– – ﹤0.01% 4013
2015
Q4 		$5K Hold
90
– – ﹤0.01% 3856
2015
Q3 		$4K Hold
90
– – ﹤0.01% 3975
2015
Q2 		$5K Sell
90
-629
-87% -$88.8K ﹤0.01% 3951
2015
Q1 		$128K Buy
719
+66
+10% +$14.4K ﹤0.01% 3278
2014
Q4 		$155K Sell
653
-5
-0.8% -$1.12K ﹤0.01% 3283
2014
Q3 		$147K Sell
658
-15
-2% -$3.56K ﹤0.01% 3271
2014
Q2 		$177K Buy
673
+192
+40% +$47.5K ﹤0.01% 3243
2014
Q1 		$156K Buy
+481
New +$144K ﹤0.01% 3260

Other funds holding CARM

FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
FVFIGP
Flagship Ventures Fund IV General Partner Cambridge, Massachusetts $585M AUM
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock Investment Management's CARM Position: Q2 2016 in Review

BlackRock Investment Management sold out of Carisma Therapeutics (CARM) in Q2 2016, closing a stake of 90 shares — an estimated $1K sold.

BlackRock Investment Management first reported a position in CARM in Q1 2014 and held it in 9 quarters. The position peaked at $177K in Q2 2014. 25 funds tracked by Wall St. Rank hold CARM as of Q2 2016.

  • BlackRock Investment Management reported no remaining Carisma Therapeutics position as of Q2 2016 after selling out during the quarter.
  • BlackRock Investment Management sold 90 Carisma Therapeutics shares in Q2 2016, an estimated $1K.
  • BlackRock Investment Management first reported a position in Carisma Therapeutics in Q1 2014 and held it in 9 quarters.
  • BlackRock Investment Management's Carisma Therapeutics position peaked at $177K in Q2 2014.
  • 25 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2016.

Based on BlackRock Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.